MedTrace Logo

A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1

NCT03277456 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2017-11-14

No results posted yet for this study

Summary

This is a first in human, phase I, open label study of the MVA viral vector (produced in the novel immortalised duck retinal cell line AGE1.CR.pIX) expressing the influenza antigens NP and M1 as a fusion protein, in healthy adult volunteers. MVA-NP+M1 will be given alone intramuscularly as a single dose.

There will be 1 study group and a total of 6 volunteers will be enrolled. Staggered enrollment will apply for the first three volunteers within the group.

Conditions

  • Human Volunteers

Interventions

BIOLOGICAL

MVA-NP+M1

Intramuscular injection of novel vaccine

Sponsors & Collaborators

  • University of Oxford

    collaborator OTHER

  • Barinthus Biotherapeutics

    lead INDUSTRY

Principal Investigators

  • Adrian Hill, MD · Director, The Jenner Institute, Oxford University

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-18
Primary Completion
2017-11-02
Completion
2017-11-02

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03277456 on ClinicalTrials.gov